0
0

Further Extension of Continuing Appropriations Act, 2021

11/1/2022, 5:03 PM

Congressional Summary of HR 1520

Purple Book Continuity Act of 2019

This bill modifies requirements for the Food and Drug Administration to publish information regarding biological products.

Current Status of Bill HR 1520

Bill HR 1520 is currently in the status of Bill Introduced since March 5, 2019. Bill HR 1520 was introduced during Congress 116 and was introduced to the House on March 5, 2019.  Bill HR 1520's most recent activity was Became Public Law No: 116-246. as of December 22, 2020

Bipartisan Support of Bill HR 1520

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
12
Democrat Cosponsors
10
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 1520

Primary Policy Focus

Economics and Public Finance

Potential Impact Areas

- Appropriations
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Executive agency funding and structure
- Government information and archives
- Health
- Licensing and registrations

Alternate Title(s) of Bill HR 1520

Further Extension of Continuing Appropriations Act, 2021
To amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes.
Purple Book Continuity Act of 2019
Purple Book Continuity Act of 2020
Purple Book Continuity Act of 2019
Purple Book Continuity Act of 2020
Further Extension of Continuing Appropriations Act, 2021
Making further continuing appropriations for fiscal year 2021, and for other purposes.
Purple Book Continuity Act of 2019
Purple Book Continuity Act of 2019

Comments